Related Experiment Video

Updated: May 11, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Combination molecularly targeted drug therapy in metastatic melanoma: progress to date

Charlotte Lemech1, Jeffrey Infante, Hendrik-Tobias Arkenau

  • 1Sarah Cannon Research UK, 93 Harley St, London W1G 6AD, UK.

Drugs
|May 8, 2013
PubMed

Insights

Novel treatments for metastatic melanoma target the mitogen-activated protein kinase (MAPK) pathway, offering initial benefits but facing resistance. Combination therapies, like dabrafenib and trametinib, aim to improve durability and overcome resistance mechanisms.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Metastatic melanoma historically had limited survival, between 6-12 months.
  • Novel treatments targeting the mitogen-activated protein kinase (MAPK) pathway offer clinical benefit.
  • Resistance to MAPK inhibitors is common, often due to pathway reactivation or bypass signaling.

Purpose of the Study:

  • To discuss currently available molecularly targeted agents for metastatic melanoma.
  • To review the development of combination therapies to overcome resistance.
  • To explore strategies targeting the PI3K pathway, angiogenesis, and the immune system.

Main Methods:

  • Review of molecularly targeted agents for metastatic melanoma.
  • Analysis of combination therapy strategies.
  • Discussion of resistance mechanisms and potential toxicities.

Main Results:

  • BRAF and MEK inhibitors provide rapid clinical benefit but limited durability.
  • Combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) shows promising clinical results with improved toxicity.
  • Other combination strategies are under development, requiring toxicity monitoring.

Conclusions:

  • Combination therapies are crucial for overcoming resistance in metastatic melanoma.
  • Targeting the MAPK pathway remains a key strategy, with ongoing development of novel combinations.
  • Careful monitoring for overlapping toxicities is essential for combination treatments.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...